ARCHIVES

Bush Increase For NIH In Sharp Contrast To Cuts In Health Delivery Programs.

This article is from The Cancer Letter archive.

Vol. 27 No. 14 | April 6, 2001

Download PDF Visit The Full Archive

Related Articles

Also FDA clarifies data requirements for phase I IND applications.

April 29, 2005

FDA Likely To Change Procedures For Patient Interaction, Official Says

November 10, 1995

Bristol-Myers Squibb To Purchase DuPont Pharmaceuticals For $7.8 Billion.

June 29, 2001

VeriStrat Biomarker Test Predicts Treatment Outcomes In Phase III NSCLC Trial

May 30, 2014

House Committee Allocates NCI $1.347 Billion, $189 Million Over President’s Request For 1987

August 1, 1986

Phase III Trial Retrospective Analysis Finds Talimogene Laherparepvec Reduced Tumors

March 28, 2014